{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:50:47Z","timestamp":1791229847665,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.ejca.2007.07.010","type":"journal-article","created":{"date-parts":[[2007,8,22]],"date-time":"2007-08-22T07:13:20Z","timestamp":1187766800000},"page":"2124-2133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis"],"prefix":"10.1016","volume":"43","author":[{"given":"Lucio","family":"Tentori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Miguel","family":"Lacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Muzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa Susanna","family":"Dorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Leonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Scarsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ruffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wokee","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Stoppacciaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Colarossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2007.07.010_bib1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/bies.1115","article-title":"Physiology and pathophysiology of poly(ADP-ribosyl)ation","volume":"23","author":"Burkle","year":"2001","journal-title":"BioEssays"},{"key":"10.1016\/j.ejca.2007.07.010_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/pr.54.3.375","article-title":"The therapeutic potential of poly(ADP-ribose) polymerase inhibitors","volume":"54","author":"Virag","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ejca.2007.07.010_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.phrs.2005.02.010","article-title":"Chemopotentiation by PARP inhibitors in cancer therapy","volume":"52","author":"Tentori","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejca.2007.07.010_bib4","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood.V99.6.2241","article-title":"Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing haematologic malignancy at the central nervous system site","volume":"99","author":"Tentori","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.07.010_bib5","first-page":"5370","article-title":"Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma","volume":"9","author":"Tentori","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.07.010_bib6","first-page":"415","article-title":"Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumours","volume":"26","author":"Tentori","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2007.07.010_bib7","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1096\/fj.06-5916fje","article-title":"Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan\/temozolomide efficacy against colon carcinoma","volume":"20","author":"Tentori","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.ejca.2007.07.010_bib8","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1038\/sj.onc.1207984","article-title":"Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair","volume":"23","author":"Veuger","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2007.07.010_bib9","first-page":"371","article-title":"Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor","volume":"2","author":"Miknyoczki","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2007.07.010_bib10","doi-asserted-by":"crossref","first-page":"5244","DOI":"10.1074\/jbc.C300437200","article-title":"Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing","volume":"279","author":"Malanga","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2007.07.010_bib11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.coph.2006.02.004","article-title":"Inhibition of poly(ADP-ribose) polymerase in cancer","volume":"6","author":"Plummer","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ejca.2007.07.010_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.phrs.2005.02.013","article-title":"Clinical perspectives of PARP inhibitors","volume":"52","author":"Graziani","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejca.2007.07.010_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2007.07.010_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2007.07.010_bib15","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2007.07.010_bib16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2007.07.010_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0065-230X(05)93005-4","article-title":"Soluble mediators of inflammation during tumour development","volume":"93","author":"Robinson","year":"2005","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.ejca.2007.07.010_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.phrs.2005.02.016","article-title":"Shock, inflammation and PARP","volume":"52","author":"Cuzzocrea","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejca.2007.07.010_bib19","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1158\/0008-5472.CAN-05-3050","article-title":"Inhibition of poly(ADP-ribose) polymerase modulates tumour-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis","volume":"66","author":"Martin-Oliva","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2007.07.010_bib20","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbrc.2006.09.160","article-title":"Poly(ADP-ribose)polymerase inhibition decreases angiogenesis","volume":"350","author":"Rajesh","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejca.2007.07.010_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.bbrc.2006.09.049","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis","volume":"350","author":"Rajesh","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejca.2007.07.010_bib22","first-page":"525","article-title":"Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs","volume":"27","author":"Tentori","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2007.07.010_bib23","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/labinvest.3780385","article-title":"Generation of human pulmonary microvascular endothelial cell lines","volume":"81","author":"Krump-Konvalinkova","year":"2001","journal-title":"Lab Invest"},{"key":"10.1016\/j.ejca.2007.07.010_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1101\/gad.9.5.509","article-title":"Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease","volume":"9","author":"Wang","year":"1995","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejca.2007.07.010_bib25","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/jpet.300.3.862","article-title":"Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure","volume":"300","author":"Pacher","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejca.2007.07.010_bib26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0006-2952(01)00935-2","article-title":"BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumour activity","volume":"63","author":"Racz","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejca.2007.07.010_bib27","first-page":"369","article-title":"Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure","volume":"17","author":"Pacher","year":"2006","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ejca.2007.07.010_bib28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm0603-677","article-title":"Regulation of angiogenesis by hypoxia: role of the HIF system","volume":"9","author":"Pugh","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2007.07.010_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2005.12.148","article-title":"IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase","volume":"341","author":"Beckert","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejca.2007.07.010_bib30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0968-0004(03)00193-2","article-title":"VEGF-receptor signal transduction","volume":"28","author":"Cross","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.ejca.2007.07.010_bib31","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1096\/fj.05-5137fje","article-title":"VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumour neovascularization","volume":"20","author":"Li","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.ejca.2007.07.010_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ejca.2007.07.010_bib33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0092-8674(03)00433-1","article-title":"PARP goes transcription","volume":"113","author":"Kraus","year":"2003","journal-title":"Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804907005242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804907005242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:16:36Z","timestamp":1760732196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804907005242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":33,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0959804907005242"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2007.07.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2007.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}